`
`
`
`
`
`
`Paper No. 19
`Filed: September 28, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`
`Patent Owner.
`
`__________________
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`__________________
`
`PATENT OWNER’S OBJECTIONS TO PETITIONER’S
`PRE-INSTITUTION EVIDENCE
`
`
`
`Case IPR2022-00722
`Patent No. 7,041,786
`
`I.
`
`INTRODUCTION
`Patent Owner Bausch Health Ireland Limited objects to Petitioner Mylan
`
`Pharmaceuticals Inc.’s Exhibits for failure to comply with the Federal Rules of
`
`Evidence (FRE). 37 C.F.R. §§ 42.62(a), 42.64(b)(1).
`
`II. OBJECTIONS
`A. Mylan’s technical exhibits (EX1006-1008, 1010-1053) are hearsay
`without exception and unauthenticated.
`
`Mylan offers EX1006-1008, 1010-1053 as non-testimony evidence to prove
`
`the truth of the matter Mylan asserts, without identifying any exception to support
`
`such use, in violation of FRE 802. Mylan’s reliance on statements the Patent Owner
`
`cannot cross examine is prejudicial. Additionally, Mylan makes no attempt to
`
`establish the authenticity of EX1006-1008, 1010-1053, in violation of FRE 901.
`
`B. Mylan’s Highlights of Prescribing Information (EX1055) is not prior
`art
`
`Mylan offers highlights of prescribing Information (EX1055) of Trulance®,
`
`
`
`which is not prior art. Thus, the Patent Owner objects to Mylan’s reliance on
`
`EX1055 for any prior art purpose.
`
`1
`
`
`
`
`Case IPR2022-00722
`Patent No. 7,041,786
`C. Mylan’s Webpage Article (EX1028) is incomplete and
`unauthenticated
`
`
`Mylan offers an incomplete webpage article (EX1028), as its sentences and
`
`Figure 1 are cut off. See FRE 106. Additionally, Mylan makes no attempt to
`
`establish the authenticity of EX1028, in violation of FRE 901.
`
`D. Each Mylan’s exhibit must be restricted to the purpose for which
`Mylan offered the exhibit
`
`Each Mylan exhibit must be restricted to the purpose for which Mylan offered
`
`the exhibit. See FRE 105. Should Mylan rely on an exhibit for a different purpose
`
`than that for which it has been offered, Bausch reserves the right to make additional
`
`objections.
`
`III. CONCLUSION
`Bausch submits these objections as authorized by Board rules.
`
`
`
`Date: September 28, 2022
`
`Respectfully submitted,
`
`
`
`
`/Justin J. Hasford/
`By:
`Justin J. Hasford, Reg. No. 62,180
`Bryan C. Diner, Reg. No. 32,409
`Joshua L. Goldberg, Reg. No. 59,369
`Caitlin E. O’Connell, Reg. No. 73,934
`Kyu Yun Kim. Reg. No. 72,783
`
`Finnegan, Henderson, Farabow,
` Garrett & Dunner, LLP
`
`Counsel for the Patent Owner
`
`2
`
`
`
`
`Case IPR2022-00722
`Patent No. 7,041,786
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of this paper was served electronically
`
`via email on September 28, 2022, in their entirety on the following:
`
`Jad Mills
`Richard Torczon
`Nicole Stafford
`Dennis Gregory
`701 Fifth Avenue, Suite 5100,
`Seattle, WA 98104-7036
`jmills@wsgr.com
`rtorczon@wsgr.com
`nstafford@wsgr.com
`dgregory@wsgr.com
`4863-5899-2145@mail.vault.netdocuments.com
`
`The Petitioner has consented to service by electronic mail.
`
`
`
`
`
`
`
`
`
`
`
`/Geneva Eaddy/
`Geneva Eaddy
`Case Manager
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER LLP
`
`Dated: September 28, 2022
`
`
`
`
`
`
`
`
`
`